PP-405 is an experimental topical drug that tries to wake hair follicle stem cells that have gone dormant, rather than to slow the hormonal process that put them to sleep.1 It is not approved, it is not available, and as of 14 October 2026 it has dosed the first patient in a twelve-month trial of roughly six hundred men.2 Everything else written about it descends from one mechanism paper and one small safety study, and the distance between those two documents and a bottle on your shelf is the whole of what follows.
What PP-405 actually is
PP-405 is a small-molecule inhibitor of the mitochondrial pyruvate carrier, applied to the scalp. That sentence is doing a great deal of work, so take it apart.
A hair follicle stem cell sits in the bulge of the follicle and spends most of its life doing nothing. When it is called on, it divides, and a new hair is built beneath it. What decides whether it answers the call turns out to be metabolic rather than hormonal. In 2017 a group at UCLA showed that these cells run on glycolysis and produce far more lactate than the skin cells around them, that deleting lactate dehydrogenase A stopped them activating altogether, and that deleting the mitochondrial pyruvate carrier — the gate that lets pyruvate into the mitochondrion — raised lactate and accelerated the hair cycle.1
Read that last clause again, because it is the entire premise of the drug. The carrier is a brake. Block the brake, lactate accumulates, and the stem cell wakes. The same paper showed that a compound doing exactly this could induce the hair cycle when applied topically to skin.1 PP-405 is the clinical descendant of that compound.
Minoxidil and finasteride argue with the process that is shutting your follicle down. PP-405 ignores the argument and tries to wake the follicle up.
This matters for who the drug is aimed at. A follicle that has miniaturised is not a follicle that has died, and the distinction is the one most men get wrong about their own scalp. Miniaturised follicles are still there, still cycling, producing hair too fine and too short to cover anything. A drug that reactivates dormant follicular units is working on tissue that still exists. It has nothing to offer scar tissue, and nothing to offer a scalp where the follicles are genuinely gone.
What the Phase 2a trial showed, and what it did not
Pelage Pharmaceuticals, the company developing PP-405, reported Phase 2a results on 17 June 2025.3 Seventy-eight men and women with androgenetic alopecia applied either PP-405 or a placebo once daily for four weeks and were followed to twelve. The study met its primary endpoint, and its primary endpoint was safety. The drug was well tolerated and no systemic absorption was detected in blood.3
One efficacy figure escaped that study and has been repeated everywhere since. At week eight, among men with a higher degree of hair loss, 31% of those treated showed a greater than 20% increase in hair density, against 0% of those on placebo.3
That number is real, it was reported by the company, and it is the most misread figure in hair loss at the moment. Four things are true about it at once. It came from a trial designed to measure safety, not efficacy. It describes a subgroup rather than everyone enrolled. It was an exploratory measure, which in trial grammar means it was looked at, not tested. And a placebo arm scoring exactly zero in a group this small tells you as much about the size of the group as about the strength of the drug.
None of that makes the result unimpressive. A topical applied for four weeks that produces a visible density change by week eight is faster than anything currently on the market, where six to twelve months is the honest conversation. It makes the result preliminary, which is a different word, and the difference is the one a careful reader should hold on to.
Those results were presented at the American Academy of Dermatology annual meeting in Denver on 28 March 2026 by Arash Mostaghimi, vice chair of clinical trials and innovation at Brigham and Women’s Hospital and associate professor at Harvard Medical School, in a session on emerging treatments targeting dormant follicles.4
What the AWAKEN trial is testing
On 14 October 2026 Pelage announced the first patient dosed in AWAKEN, a randomised, double-blind, placebo-controlled study running twelve months in roughly 600 adult men with Norwood-Hamilton Type IV or V androgenetic alopecia, across the United States and Canada.2 It is registered as NCT07819435.5
The trial will assess change in non-vellus target area hair count, a patient-reported outcome, and measures of follicular reactivation.2 Non-vellus target area hair count is worth knowing by name: a defined patch of scalp is tattooed or marked so the same square centimetre is photographed each visit, and only terminal hairs are counted, with the fine vellus hairs excluded. It is the standard currency of hair trials because it is hard to argue with.
Note what this design tells you about the company's own confidence. A twelve-month placebo-controlled study in six hundred men at Norwood IV to V is not a cautious trial. It is a trial built to produce an answer that regulators will accept, in men with substantial loss, measured by the method hardest to flatter.
Note also who is not in it. AWAKEN enrolls men. Pelage's chief medical officer has said plainly that the biology of androgenetic alopecia differs in important ways between men and women.2 A woman reading about PP-405 today is reading about a drug not yet being tested in her.
When could you actually use it
Work the arithmetic yourself. A twelve-month study that dosed its first patient in October 2026 finishes enrolling, then runs its course, then reports — which puts a readout no earlier than late 2027 and realistically into 2028. Regulatory review follows a successful readout, and adds its own year or more. The earliest honest answer is 2028 to 2029, and that answer assumes the drug works, which is precisely the question AWAKEN exists to settle.
Anyone offering you PP-405 before then is not offering you PP-405.
What this does not change about what you do now
A drug three years out should not alter your next three years. If your hair is thinning, the question that governs everything is still whether what you have is androgenetic alopecia at all, because a telogen effluvium, a scalp inflammation and a traction pattern all look like thinning in the mirror and respond to entirely different things. That question is answered by examination, not by reading.
The follicles PP-405 would one day work on are the ones you still have. Everything that keeps a follicle alive and cycling between now and 2029 — treating the scalp condition you actually have, maintaining whatever is currently holding ground, not waiting out a decline on the strength of a press release — is what determines how much of your scalp is still eligible when the question gets answered.
That is the part worth sitting with. The trial will report with or without you. What you can decide is how much scalp is still worth waking when it does.
Questions I am asked in the chair
Can I get PP-405 now?
No. It is an investigational drug in trials and is not approved or sold anywhere. Nothing marketed as PP-405 or as its equivalent is PP-405.
Can I join the trial?
AWAKEN is enrolling adult men with Norwood-Hamilton Type IV or V androgenetic alopecia in the United States and Canada.2 Eligibility, sites and contact details live on the registry record, NCT07819435, which is the document to read rather than any summary of it.5
Does PP-405 work for women?
Unknown. Women were included in the Phase 2a safety study, but the reported density finding was in men, and the AWAKEN trial enrolls men only.2,3
Will it replace finasteride and minoxidil?
There is no evidence either way, and the mechanisms do not compete. PP-405 acts on stem cell metabolism; finasteride acts on the hormonal conversion driving miniaturisation. A drug that wakes follicles and a drug that stops them shutting down are, in principle, complementary rather than alternative.
Is it a cure for baldness?
No, and the word is the wrong shape for what is being tested. AWAKEN measures whether a topical increases terminal hair count over twelve months against placebo. That is a treatment question. A follicle reactivated by a drug presumably stays reactivated only while the drug continues, which is a question the twelve-month design will begin to answer and no shorter study could.
Sources
- Flores A, Schell J, Krall AS, Jelinek D, Miranda M, Grigorian M, Braas D, White AC, Zhou JL, Graham NA, Graeber T, Seth P, Evseenko D, Coller HA, Rutter J, Christofk HR, Lowry WE. Lactate dehydrogenase activity drives hair follicle stem cell activation. Nature Cell Biology. 2017;19(9):1017–1026.
- Pelage Pharmaceuticals. First patient dosed in Phase 2/3 AWAKEN trial of PP405 for androgenetic alopecia. 14 October 2026.
- Pelage Pharmaceuticals. Positive Phase 2a clinical trial results for PP405 in regenerative hair loss therapy. 17 June 2025.
- Mostaghimi A. Emerging treatments for hair loss targeting dormant follicles. American Academy of Dermatology Annual Meeting, Denver, 28 March 2026.
- ClinicalTrials.gov. A study of PP405 in androgenetic alopecia (AWAKEN). Identifier NCT07819435.
Written by Itzy J., Licensed Barber & Barber-Cosmetology Instructor, at the Owls & Wolves Atelier, 18 N Marengo Ave, Pasadena, California. Published 20 September 2026. This article describes hair fiber and water chemistry and is general information rather than medical advice. Hair loss with a sudden onset, an unusual pattern, or an inflamed or painful scalp is worth a dermatologist’s eyes rather than a barber’s.